260 results about "Defensin" patented technology

Methods and compositions for modulating development and defense responses are provided. Nucleotide sequences encoding defensin proteins are provided. The sequences can be used in expression cassettes for modulating development, developmental pathways, and defense responses. Transformed plants, plant cells, tissues, and seed are also provided.

The invention relates to compositions comprising at least one peptide with a structure or structural pattern of β-defensin 2 and / or its derivatives, especially human β-defensin 2. The compositions are selected in particular from cosmetic and / or pharmaceutical compositions, cleaning and / or washing agents, water-treatment agents and cooling lubricants. The invention also relates to the use of peptides with a structure or structural pattern of β-defensin 2 and / or its derivatives, especially human β-defensin 2, as an antimicrobial active ingredient in the aforementioned agents.

Methods for the treatment and prevention of microbial infection, such as infections caused by bacteria, viruses, fungi and parasites are disclosed, as are adjuvants for use with vaccines against such microbes. The methods use porcine β-defensins, such as porcine β-defensin-1 and are particularly useful for treating or preventing infections caused by gram-negative bacteria, such as pertussis.

Disclosed herein is a composition and a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and / or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the bodies response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin, and defensins were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.

The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.

The invention mainly relates to an application of defensins to an aspect of preparation of a medicine for treating metabolic syndrome. Inventiveness and exploitativeness of the invention are reflected in that human derived alpha defensins 5 and 6 is supplemented via oral administration to balance intestinal flora ecology, so that system inflammation is reduced; insulin resistance is relieved; the fatty liver is ablated; and blood fat and blood sugar are reduced. The invention further provides a method for preparing the alpha defensins 5 and 6, and the application of the alpha defensins 5 and 6 to the medicine for treating related diseases.

The present invention relates to a method for diagnosing colon cancer by detecting a colon cancer specific antigen, defensin α6 from the blood of patient and a diagnostic kit for colon cancer comprising anti-defensin α6 antibody. The diagnostic kit for colon cancer of present invention comprises: a solid support such as 96-well plate for ELISA, nitrocellulose membrane, polyvinylidene fluoride membrane, microplate, glass substrate, polystyrene substrate, silicone substrate or metal plate, on which anti-defensin α6 antibody is immobilized; and, a means for detecting colon cancer specific antigen such as a primary antibody which specifically binds with an antigen conjugated with an antibody on a solid substrate and a secondary antibody-signal complex which specifically binds with the primary antibody. The diagnostic kit of the invention can diagnose colon cancer with the minute amount of patients' blood, which makes possible the easy and simple diagnosis of colon cancer.

The present invention relates to recombinant expression of defensin antimicrobial peptides in fermentation of filamentous fungi.

The present invention provides a preparing method of a porcine defensins engineering yeast strain, firstly, the porcine defensins gene is modified by method of genetic site-directed mutagenesis, mutant of porcine defensins gene having high biological activity is screened, then the porcine defensins gene which codon is optimized is artificially synthesized by the conventional codon of yeast strain, the engineering yeast strain having high yield, strong biological activity for producing porcine defensins is obtained by multiple screens. The porcine defensins engineering yeast strain kills the yeast by heating after fermented, directly used as feed additive by concentrated, having no separating and extracting courses, reducing the production cost of the defensins, improving the economic effect of the production enterprise. The invention provides conditions for mass industrial production of defensins, resolving the displacement of the porcine feed antibiotics additive.

No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU / ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of β-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus.

Drug compositions for treatment of one or more inflammatory conditions can includes at least one of a θ-defensin, analog or derivative thereof. Inventive methods include researching θ-defensins, analogs or derivatives thereof for their efficacy with respect to anti-inflammatory effects, and providing such compositions to the marketplace for the purpose of treating inflammatory conditions. Of particular interest are drug compositions effective to produce clinically relevant inhibition of tumor necrosis factor alpha (TNF-α)-converting enzyme (TACE) or other proinflammatory proteases, and / or sheddases. it is contemplated that preferred compositions can be used to treat rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory diseases, autoimmune diseases, cancer, and Alzheimer's, osteoarthritis, inflammation-related neurodegenerative and other inflammation-related diseases.

The invention discloses a lactobacillus reuteri 22 and application thereof. The lactobacillus reuteri 22 disclosed by the invention is separated from healthy chicken flocks, is classified and named aslactobacillus reuteri, and has a preservation number of CGMCC No.17932. By detecting the performance of probiotics, the invention finds that the lactobacillus reuteri 22 has good acid resistance, cholate resistance and adhesion performance, and can inhibit growth of pathogenic bacteria. Through Animal assays, in a healthy physiological state, the lactobacillus reuteri 22 does not influence the level of inflammatory factors, but can increase the number of goblet cells and promote the increase of expression levels of related genes such as compact protein, defensin and lysozyme, can increase thelength of intestinal villi and the depth of crypt, and has the potential of maintaining intestinal mucosa barriers. Therefore, the strain is expected to be developed into probiotics for maintaining achicken intestinal mucosa barrier and guaranteeing green and healthy chicken breeding.

[PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor.[SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient.[EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and β-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.

The invention provides lipopeptid which comprises a peptide chain and an aliphatic chain which are connected through peptide bonds, wherein the molecular weight of the lipopeptid is 2848Da, and the lipopeptid is linear, and can obviously introduce the expression of phylaxin, and effectively inhibit staphylococcus aureus infection so as to prevent or reduce skin infection. The invention also discloses a derivative of the lipopeptid and preparation methods and application of the lipopeptid and the derivative of the lipopeptid.

The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3α / CCL20 or β-defensin mDF2β. The invention further provides cancer vaccines and methods for treating subjects having, or at risk of developing, cancer.

The invention relates to defensin mNP-1 which utilizes chlorella to express modified rabbit defensin NP-1(Mnp-1), the defensin expressed in the chlorella has strong inhibition or skilling effect on bird flu virus H5N1 and H9N2. The result of the invention can be applied for preparing anti-influenza virus drugs.

The invention discloses a reagent kit and a method for detecting human alpha defensin 1 / 3 gene copy number. The reagent kit comprises a first group of primers, i.e. target gene real-time fluorescence quantitative PCR (Polymerase Chain Reaction) amplification primers, a first fluorescent probe, i.e. a target gene real-time fluorescence quantitative PCR amplification fluorescent probe, a second group of primers, i.e. a reference gene real-time fluorescence quantitative PCR amplification primers, a second fluorescent probe, i.e. a target gene real-time fluorescence quantitative PCR amplification fluorescent probe, a calibration sample DNA (Deoxyribose Nucleic Acid), and real-time fluorescence quantitative PCR reaction liquid, wherein base sequences of the first group of primers is shown by SEQ (Sequence) ID (Identity) No. 1 and 2; a middle probe base sequence is shown by SEQ ID No. 3; base sequences of the second group of primers are shown by SEQ ID No. 4 and 5; a middle probe base sequence is shown by SEQ ID No. 6. The reagent kit for detecting the human alpha defensin 1 / 3 gene copy number has the advantages of simplicity, convenience and quickness in use, no standard curve required, high sensitivity and specificity, good repeatability and high detection efficiency and can be used for indicating the risk prediction of clinical infection immune diseases.

The invention relates to defensin cathelicidin-PP of polypedates puerensis as well as a gene and application thereof, and belongs to the field of biomedicine. The defensin cathelicidin-PP is a cyclic polypeptide encoded by a gene of defensin of Chinese amphibian polypedates puerensis, and has a molecular weight of 3,366.08 daltons and an isoelectric point of 10.05; the amino acid sequence of the defensin cathelicidin-PP is as shown by SEQ ID NO: 1. A gene GenBank Accession KY610282 for encoding a precursor of the defensin cathelicidin-PP of the polypedates puerensis consists of 615 nucleotide sequences; the nucleotide sequence of the gene GenBank Accession KY610282 is as shown by SEQ ID NO: 2, wherein nucleotides at No. 346 to No. 441 sites are encoding genes of defensin cathelicidin-PP of mature polypedates puerensis. The invention relates to the application of the defensin cathelicidin-PP of the polypedates puerensis to the preparation of a therapeutic medicine for infectious diseases caused by escherichia coli, salmonella paratyphi A, pseudomonas aeruginosa and candida glabrata. The defensin cathelicidin-PP has the obvious effects of inhibiting the growth of a bacterium and a fungus for the escherichia coli, the salmonella paratyphi A, the pseudomonas aeruginosa and the candida glabrata.

The present invention relates to a defensin-albumin anti-tumor fusion protein comprising the following structure: defensin HBD2-connecting peptide (G4S) 2-human serum albumin HSA; wherein the human beta-defensin 2 (HBD2) has an amino acid sequence shown in SEQ ID NO: 1, the HAS has an amino acid sequence shown in SEQ ID NO: 2, the novel anti-tumor fusion protein has albumin macropinocytosis targeting property and the tumor cell killing function of the human beta-defensin 2 (HBD2), and is expected to be developed into a new class of anticancer drugs.

A cationic antimicrobial peptide (CAMP) conjugate is disclosed. The CAMP conjugate may be made by identifying a suitable carrier peptide; identifying a suitable antimicrobial agent; creating a conjugate by conjugating the peptide with the antimicrobial agent; and evaluating and refining the conjugate. The peptide may be short peptide based on the sequence of a CAMP, such as human β-defensin-3. The peptide can be directly connected to the antimicrobial agent or through a linker segment. The antimicrobial agent may be connected to the peptide or the linker segment through stable or cleavable bonding. The peptide may carry and facilitate the delivery of the conjugated antimicrobial agent to a microbe.

The invention expresses a refitted rabbit defensin NP-1 (mNP-1) by using chlorella. The defensin expressed in chlorella has a very strong inhibiting or killing effect on Gram-negative bacteria, Gram-positive bacteria and the like, and can be used for killing medicament-resistant bacteria. A result of the invention can be applied to preparation of a medicament which is resistant to the Gram-negative bacteria and the Gram-positive bacteria, and can be applied to preparation of medicament which is resistant to super bacteria.

A housefly alexin cDNA and its clone method is disclosed in the invention. The housefly alexin has sequences of SEQ ID No.1 and SEQ ID NO.2. The clone method of the invention is: distilling general RNA or mRNA from housefly, reverse transcripting into Cdna; designing introduction on the basis of alexin conservative sequence, extending to a DNA segment via the chain-type polymerase reaction, purificating extension outcome, cloning in the purificated outcome to the pGEM-TEasy carrier, converting HD5 alpha cell, flat cultivating after a night. The housefly alexin may use of producing medicine product by gene recombining technology, expressing in the escherichia coli and microzyme and getting the housefly alexin having the antibacterium function.

Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.

The present invention provides production process of human alpha phylaxin-1 protein with colibacillus and the optimized designed DNA sequence and recombinant expression plasmid. The production process includes: optimizing design with alpha phylaxin-1 mature peptide code sequence to obtain sequence SEQ ID No. 1; constituting prokaryotic expression vector plasmid pET32a-mHNP1, introducing the plasmid into colibacillus BL21(DE3)pLysS, and chemically inducing expression of human alpha phylaxin-1. The process can overcome the toxin of human alpha phylaxin-1 protein on host bacillus causing low or even no expression, and produce active human alpha phylaxin-1 protein in great amount for meeting the need of relevant structure and biochemical research and antibody preparation as well as for application in medical field.

The present invention relates to antibiotic synergism of pharmaceutical compositions comprising a defensin and a beta-lactam antibiotic.

The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting decreased expression of Indian Hedgehog (Ihh) and / or increased expression of Defensin A5 (DefA5) and / or Defensin A6 (DefA6) in the tissues or cells of the mammal relative to a control.